Bartosz Kozłowski1, Joanna Kubiak-Pulkowska2, Julianna Pałka1, Dominika Bożiłow1, Magdalena Zając3, Aleksander Deptuła4. 1. Anaesthesiology and Intensive Care Unit, 10th Military Research Hospital and Polyclinic, Bydgoszcz, Poland. 2. Jan Biziel University Hospital No. 2, Bydgoszcz, Poland. 3. Faculty of Pedagogy, Kazimierz Wielki University, Bydgoszcz, Poland. 4. Department of Propaedeutics of Medicine and Infection Prevention, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Abstract
OBJECTIVE: The aim of this retrospective study was to estimate the prevalence of healthcare-associated infections (HAI), microbiological data including resistance patterns and impact of HAI on patients' survival. METHODS: Two-centre study on 172 patients was performed. Medical records of patients hospitalized in the two COVID-19 intensive care units (ICU) localized in Bydgoszcz between 1 October 2020 and 30 March 2021 were analysed retrospectively. Data collection included demographics, microbiological, clinical variables, and patient outcome. All infections were defined according to the HAI-Net ICU protocol of the European Centre for Disease Prevention and Control (ECDC). Detailed data concerning bloodstream infection (BSI), pneumonia (PN) and urinary tract infection (UTI) were collected. RESULTS: In 97 patients (56.4%), 138 HAI cases were identified. Patients with HAI statistically more often had been administered antimicrobial therapy prior to the admission to ICU (59.8% vs. 34.7%, p < 0.05), and needed catecholamines during hospitalization (93.8% vs. 70.7%, p < 0.001). The risk of HAI increased by 50% if antimicrobial therapy had been applied before the admission to ICU, and was three times higher if during the hospitalization in ICU catecholamines infusion was needed. Mortality was higher in patients diagnosed with HAI (72.2% vs. 65.3%) but the difference was not statistically significant (p = 0.34). CONCLUSIONS: Further investigation of co-infections in critically ill patients with COVID-19 is required in order to identify HAI risk factors, define the role of empiric antimicrobial therapy and proper prevention strategies.
OBJECTIVE: The aim of this retrospective study was to estimate the prevalence of healthcare-associated infections (HAI), microbiological data including resistance patterns and impact of HAI on patients' survival. METHODS: Two-centre study on 172 patients was performed. Medical records of patients hospitalized in the two COVID-19 intensive care units (ICU) localized in Bydgoszcz between 1 October 2020 and 30 March 2021 were analysed retrospectively. Data collection included demographics, microbiological, clinical variables, and patient outcome. All infections were defined according to the HAI-Net ICU protocol of the European Centre for Disease Prevention and Control (ECDC). Detailed data concerning bloodstream infection (BSI), pneumonia (PN) and urinary tract infection (UTI) were collected. RESULTS: In 97 patients (56.4%), 138 HAI cases were identified. Patients with HAI statistically more often had been administered antimicrobial therapy prior to the admission to ICU (59.8% vs. 34.7%, p < 0.05), and needed catecholamines during hospitalization (93.8% vs. 70.7%, p < 0.001). The risk of HAI increased by 50% if antimicrobial therapy had been applied before the admission to ICU, and was three times higher if during the hospitalization in ICU catecholamines infusion was needed. Mortality was higher in patients diagnosed with HAI (72.2% vs. 65.3%) but the difference was not statistically significant (p = 0.34). CONCLUSIONS: Further investigation of co-infections in critically ill patients with COVID-19 is required in order to identify HAI risk factors, define the role of empiric antimicrobial therapy and proper prevention strategies.
Entities:
Keywords:
COVID-19; healthcare-associated infections; infection control; intensive care unit
Authors: Michal Walaszek; Anna Rozanska; Malgorzata Bulanda; Jadwiga Wojkowska-Mach; Polish Society Of Hospital Infections Team Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2018-03-01 Impact factor: 1.245
Authors: V Baccolini; G Migliara; C Isonne; B Dorelli; L C Barone; D Giannini; D Marotta; M Marte; E Mazzalai; F Alessandri; F Pugliese; G Ceccarelli; C De Vito; C Marzuillo; M De Giusti; P Villari Journal: Antimicrob Resist Infect Control Date: 2021-06-04 Impact factor: 4.887
Authors: Małgorzata Kołpa; Marta Wałaszek; Agnieszka Gniadek; Zdzisław Wolak; Wiesław Dobroś Journal: Int J Environ Res Public Health Date: 2018-01-11 Impact factor: 3.390
Authors: Elżbieta Rafa; Marta Z Wałaszek; Michał J Wałaszek; Adam Domański; Anna Różańska Journal: Int J Environ Res Public Health Date: 2021-02-24 Impact factor: 3.390